IP Library Granted Patent US 8,105,632
Granted Patent B2
US 8,105,632 · App. 11/792,399 · Granted Jan 31, 2012

Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders

Assignee: University of Miami
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,105,632
App. No.
11/792,399
Granted
Jan 31, 2012
Kind
B2
Abstract

Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused by chemotherapy.

Claims (13)

1. A method of increasing hemostasis comprising administering a composition comprising cell-derived microparticles that are effective to treat an excessive bleeding condition in a mammal in need thereof, wherein said microparticles are red cell derived microparticles (RMP).

2. The method of claim 1 wherein the mammal is a human.

3. The method of claim 1 wherein the excessive bleeding condition is caused by a clinical disorder.

4. The method of claim 2 wherein the human suffers from a blood clotting disorder.

5. The method of claim 2 wherein the human suffers from a disease or disorder selected from the group consisting of immune or idiopathic thrombocytopenic purpura, drug- and chemotherapy-induced thrombocytopenia, thrombocytopenias of different causes both congenital and acquired, and impaired platelet function, both congenital and acquired.

6. The method of claim 3 wherein the thrombocytopenia is induced by a chemotoxic agent.

7. The method of claim 6 wherein the chemotoxic agent is administered during chemotherapy.

8. The method of claim 1 wherein excessive bleeding condition is caused by a traumatic injury or is undergoing surgical procedures or invasive diagnostic or therapeutic procedures where bleeding and blood loss can be substantial.

9. The method of claim 1 wherein the RMP have been derived from the red blood cells of the individual to whom they are being administered.

10. A method of treating an excessive bleeding condition comprising administering a composition comprising red cell-derived microparticles that promote formation of blood clots and stimulate platelet adhesion and aggregation to a patient in need thereof.

11. The method of claim 1 wherein the dosage of microparticles is between 10 6 and 10 12 /kg.

12. The method of claim 11 wherein the dosage is between 10 8 and 10 10 /kg.

13. The method of claim 1 wherein the composition is administered intravenously.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2012
From: AHN, YEON S.; JY, WENCHE; HORSTMAN, LAWRENCE L.
To: UNIVERSITY OF MIAMI
Reel/Frame 028008/0671 →
Continuity (2)
Provisional Application 60633417 · Dec 7, 2004
Related Publication 20080069807A1 · Mar 20, 2008